Conference
A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT)
Abstract
5566
Background: The limited therapeutic index of chemotherapy in recurrent or metastatic MSGT provides a strong rationale for the evaluation of molecularly targeted agents in this disease. Lapatinib is a dual inhibitor of EGFR and ErbB2 tyrosine kinase activity. Expression of ErbB2 and EGFR has been associated with biological aggressiveness and poor prognosis in MSGT, respectively. We conducted a phase II study to determine …
Authors
Agulnik M; Cohen EE; Cohen RB; Chen EX; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Siu LL
Volume
24
Pagination
pp. 5566-5566
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 20, 2006
DOI
10.1200/jco.2006.24.18_suppl.5566
Conference proceedings
Journal of Clinical Oncology
Issue
18_suppl
ISSN
0732-183X